Akebia Therapeutics, Inc (AKBA) insider trading
Every open-market stock purchase and sale by Akebia Therapeutics, Inc executives, directors, large shareholders and members of Congress, from SEC Form 4 filings. Sector: Other.
Insider activity at a glance
- Insiders sold $963K over the last 12 months (7 sales).
- Last insider buy: John P. Butler (CEO), $86.6K, 8 months ago.
Last 12 months: insiders bought $86.6K (1 buy) and sold $963K (7 sales). Last close $0.59 on Oct 21, 2026.
Recent AKBA insider trades
| Date | Insider | Trade | Value |
|---|---|---|---|
| Aug 6, 2026 | John P. Butler (CEO) | Bought (not open market) | — |
| Jun 29, 2026 | Erik Ostrowski (CFO) | Sold | $62.2K |
| Jun 17, 2026 | Cynthia Smith (Insider) | Bought (not open market) | — |
| Jun 17, 2026 | Michael W Rogers (Insider) | Bought (not open market) | — |
| Jun 17, 2026 | Michael W Rogers (Insider) | Bought (not open market) | — |
| Jun 17, 2026 | Adrian Adams (Insider) | Bought (not open market) | — |
| Jun 17, 2026 | Adrian Adams (Insider) | Bought (not open market) | — |
| Jun 17, 2026 | Leanne M Zumwalt (Insider) | Bought (not open market) | — |
| Jun 17, 2026 | Leanne M Zumwalt (Insider) | Bought (not open market) | — |
| Jun 17, 2026 | Cynthia Smith (Insider) | Bought (not open market) | — |
| Jun 17, 2026 | Myles Wolf (Insider) | Bought (not open market) | — |
| Jun 17, 2026 | Myles Wolf (Insider) | Bought (not open market) | — |
| Jun 17, 2026 | Ron Frieson (Insider) | Bought (not open market) | — |
| Jun 17, 2026 | Ron Frieson (Insider) | Bought (not open market) | — |
| Apr 1, 2026 | Philip J. Vickers (Insider) | Bought (not open market) | — |
| Mar 4, 2026 | John P. Butler (CEO) | Bought | $86.6K |
| Feb 2, 2026 | John P. Butler (CEO) | Bought (not open market) | $247K |
| Feb 2, 2026 | John P. Butler (CEO) | Sold | $160K |
| Feb 2, 2026 | John P. Butler (CEO) | Sold | $134K |
| Feb 2, 2026 | John P. Butler (CEO) | Sold | $116K |
| Feb 2, 2026 | Nicholas Grund (C-suite exec) | Sold | $74.5K |
| Feb 2, 2026 | John P. Butler (CEO) | Sold | $64.9K |
| Feb 2, 2026 | Richard C Malabre (C-suite exec) | Sold | $50.2K |
| Feb 2, 2026 | Erik Ostrowski (CFO) | Sold | $48.6K |
| Feb 2, 2026 | Nicholas Grund (C-suite exec) | Sold | $43.4K |
Who's trading AKBA
- John P. Butler, CEO: bought $86.6K (1 buy), sold $474K (4 sales), last Aug 6, 2026
- Erik Ostrowski, CFO: sold $111K (2 sales), last Jun 29, 2026
- Adrian Adams, Insider: other filings, last Jun 17, 2026
- Ron Frieson, Insider: other filings, last Jun 17, 2026
- Michael W Rogers, Insider: other filings, last Jun 17, 2026
- Cynthia Smith, Insider: other filings, last Jun 17, 2026
- Myles Wolf, Insider: other filings, last Jun 17, 2026
- Leanne M Zumwalt, Insider: other filings, last Jun 17, 2026
- Philip J. Vickers, Insider: other filings, last Apr 1, 2026
- Nicholas Grund, C-suite exec: sold $118K (2 sales), last Feb 2, 2026
- Richard C Malabre, C-suite exec: sold $68.8K (2 sales), last Feb 2, 2026
- Carolyn M. Rucci, C-suite exec: sold $97K (3 sales), last Feb 2, 2026
- Steven Keith Burke, C-suite exec: sold $94K (3 sales), last Feb 2, 2026
Get free alerts when an insider at Akebia Therapeutics, Inc files a new trade →